This is a Validated Antibody Database (VAD) review about human HLA-A, based on 141 published articles (read how Labome selects the articles), using HLA-A antibody in all methods. It is aimed to help Labome visitors find the most suited HLA-A antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
HLA-A synonym: HLAA

BioLegend
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; 1:200
BioLegend HLA-A antibody (BioLegend, 114605) was used in flow cytometry on mouse samples at 1:200. Nat Commun (2021) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry - paraffin section; human; 1:100; fig 6
BioLegend HLA-A antibody (Biolegend, 311402) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 6). NPJ Regen Med (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2b
BioLegend HLA-A antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig 2b). BMC Biol (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:200; loading ...; fig 3d
BioLegend HLA-A antibody (BioLegend, 311410) was used in flow cytometry on human samples at 1:200 (fig 3d). J Immunother Cancer (2021) ncbi
mouse monoclonal (W6/32)
  • other; mouse; 1:100; fig 3c
BioLegend HLA-A antibody (Biolegend, 311410) was used in other on mouse samples at 1:100 (fig 3c). Cell (2021) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; 1:200; loading ...; fig s11b
BioLegend HLA-A antibody (BioLegend, 343306) was used in flow cytometry on human samples at 1:200 (fig s11b). Nat Commun (2021) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 1a
BioLegend HLA-A antibody (Biolegend, 343308) was used in flow cytometry on human samples (fig 1a). Proc Natl Acad Sci U S A (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2e, 2f, 2g
BioLegend HLA-A antibody (Biolegend, 311410) was used in flow cytometry on human samples (fig 2e, 2f, 2g). Proc Natl Acad Sci U S A (2021) ncbi
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; 1:200; fig 5a
BioLegend HLA-A antibody (Biolegend, 28-8-6) was used in flow cytometry on mouse samples at 1:200 (fig 5a). Nat Commun (2021) ncbi
mouse monoclonal (W6/32)
  • ELISA; human
BioLegend HLA-A antibody (BioLegend, 311402) was used in ELISA on human samples . Science (2021) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig s1b
BioLegend HLA-A antibody (Biolegend, 343303) was used in flow cytometry on human samples (fig s1b). Nat Commun (2020) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; 1:50; loading ...
BioLegend HLA-A antibody (Biolegend, BB7.2) was used in flow cytometry on human samples at 1:50. Sci Signal (2020) ncbi
mouse monoclonal (28-8-6)
BioLegend HLA-A antibody (BioLegend, 28-8-6) was used . Nature (2020) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:75; loading ...; fig 2b
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples at 1:75 (fig 2b). Nature (2020) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:100; loading ...; fig s20c
BioLegend HLA-A antibody (Biolegend, 311403) was used in flow cytometry on human samples at 1:100 (fig s20c). Nat Commun (2020) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2e
BioLegend HLA-A antibody (Biolegend, 311413) was used in flow cytometry on human samples (fig 2e). Stem Cell Res Ther (2020) ncbi
mouse monoclonal (BB7.2)
BioLegend HLA-A antibody (BioLegend, BB7.2) was used . J Virol (2020) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; 1:100; fig e9c
BioLegend HLA-A antibody (BioLegend, 114507) was used in flow cytometry on mouse samples at 1:100 (fig e9c). Nature (2019) ncbi
mouse monoclonal (SF1-1.1)
  • flow cytometry; mouse; 1:100; fig 5e
BioLegend HLA-A antibody (BioLegend, 116608) was used in flow cytometry on mouse samples at 1:100 (fig 5e). Nature (2019) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples . JCI Insight (2019) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; loading ...; fig 3h
BioLegend HLA-A antibody (Biolegend, 114507) was used in flow cytometry on mouse samples (fig 3h). Oncoimmunology (2019) ncbi
mouse monoclonal (28-8-6)
  • mass cytometry; mouse; loading ...; fig 3, s2
BioLegend HLA-A antibody (Biolegend, 114602) was used in mass cytometry on mouse samples (fig 3, s2). Science (2019) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; mouse; loading ...; fig s5b
BioLegend HLA-A antibody (BioLegend, 311426) was used in flow cytometry on mouse samples (fig s5b). Nat Immunol (2019) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; 10 ug/ml; fig 4i
BioLegend HLA-A antibody (Biolegend, 311427) was used in blocking or activating experiments on human samples at 10 ug/ml (fig 4i). Cancer Cell (2019) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s8
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig s8). Nat Commun (2019) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; loading ...; fig 2d
BioLegend HLA-A antibody (BioLegend, 28-14-8) was used in flow cytometry on mouse samples (fig 2d). PLoS ONE (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 3
BioLegend HLA-A antibody (BioLegend, 311410) was used in flow cytometry on human samples (fig 3). J Virol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 5a
BioLegend HLA-A antibody (Biolegend, 311425) was used in flow cytometry on human samples (fig 5a). Stem Cells Transl Med (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s1
BioLegend HLA-A antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig s1). JCI Insight (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2l
BioLegend HLA-A antibody (BioLegend, 311426) was used in flow cytometry on human samples (fig 2l). Cancer Res (2018) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 3c
BioLegend HLA-A antibody (Biolegend, 343317) was used in flow cytometry on human samples (fig 3c). J Virol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:50; fig 2a
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples at 1:50 (fig 2a). Nat Immunol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 5b
BioLegend HLA-A antibody (BioLegend, w6/32) was used in flow cytometry on human samples (fig 5b). J Virol (2018) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 1a, 6a
BioLegend HLA-A antibody (BioLegend, BB7.2) was used in flow cytometry on human samples (fig 1a, 6a). J Virol (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s1b
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig s1b). Nature (2017) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; loading ...
BioLegend HLA-A antibody (BioLegend, w6/32) was used in blocking or activating experiments on human samples . J Immunol (2017) ncbi
mouse monoclonal (W6/32)
  • immunocytochemistry; human; 1:500; loading ...; fig 1a
BioLegend HLA-A antibody (BioLegend, W6/32) was used in immunocytochemistry on human samples at 1:500 (fig 1a). J Cell Sci (2017) ncbi
mouse monoclonal (28-8-6)
  • immunohistochemistry; mouse; loading ...; fig s3c
In order to evaluate host immune-mediated cell rejection in a retinal transplantation model, BioLegend HLA-A antibody (Biolegend, 114603) was used in immunohistochemistry on mouse samples (fig s3c). Cell Stem Cell (2017) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig e6a
In order to report preclinical studies using a CRISPR-based methodology to target hematopoietic stem cells to treat beta-haemoglobinopathies, BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig e6a). Nature (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 2e
In order to investigate the role of Eomes in the retention of liver natural killer cells, BioLegend HLA-A antibody (BioLegend, BB7.2) was used in flow cytometry on human samples (fig 2e). J Immunol (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 3e, 3f
BioLegend HLA-A antibody (BioLegend, BB7.2) was used in flow cytometry on human samples (fig 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 3e, 3f
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; fig 2
BioLegend HLA-A antibody (Biolegend, BB7.2) was used in flow cytometry on human samples (fig 2). Sci Rep (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples . J Exp Med (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig s1
BioLegend HLA-A antibody (BioLegend, BB7.2) was used in flow cytometry on human samples (fig s1). J Clin Invest (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1a
In order to assess the effects of platelet-derived ectosomes on natural killer cells, BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (SF1-1.1)
  • flow cytometry; mouse; loading ...; fig 1a
BioLegend HLA-A antibody (BioLegend, SF 1-1.1) was used in flow cytometry on mouse samples (fig 1a). Cancer Immunol Immunother (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig s2
In order to determine modulation of presentation of cell surfaced calreticulin by alpha-integrin function and expression, BioLegend HLA-A antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig s2). Cell Death Dis (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 3c
BioLegend HLA-A antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig 3c). J Immunol (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 5a
BioLegend HLA-A antibody (Biolegend, BB7.2) was used in flow cytometry on human samples (fig 5a). J Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; tbl 1
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples (tbl 1). J Immunol (2016) ncbi
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; fig 2
In order to study the requisite for the function of regulatory T cells known as phosphatase PP2A, BioLegend HLA-A antibody (Biolegend, 114612) was used in flow cytometry on mouse samples (fig 2). Nat Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig s6b
In order to test if AML patients treated decitabine have induced expression of cancer testis antigens, BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig s6b). Oncotarget (2016) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; 1:200; fig s1
In order to assess the role of NLRC5 to NK-T-cell crosstalk, BioLegend HLA-A antibody (BioLegend, 28-14-8) was used in flow cytometry on mouse samples at 1:200 (fig s1). Nat Commun (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:100; fig 2
BioLegend HLA-A antibody (Biolegend, W6/32) was used in flow cytometry on human samples at 1:100 (fig 2). Nat Commun (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 5
BioLegend HLA-A antibody (Biolegend, 311404) was used in flow cytometry on human samples (fig 5). Br J Cancer (2015) ncbi
mouse monoclonal (SF1-1.1)
  • flow cytometry; mouse; loading ...; fig 2c
BioLegend HLA-A antibody (Biolegend, SF1-1.1) was used in flow cytometry on mouse samples (fig 2c). Transpl Immunol (2015) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; fig 2
BioLegend HLA-A antibody (BioLegend, 343304) was used in flow cytometry on human samples (fig 2). J Biol Chem (2015) ncbi
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; loading ...; fig 4d
In order to determine if therapeutic antiviral T cells eliminate viral load in the brain of mice persistently infected from birth with lymphocytic choriomeningitis virus without causing blood-brain barrier breakdown or tissue damage, BioLegend HLA-A antibody (BioLegend, 28-8-6) was used in flow cytometry on mouse samples (fig 4d). J Exp Med (2015) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry; human; 1:50
In order to investigate the dynamics and characteristics of natural killer cell types in the human ocular mucosal surface in situ during infection with group D human adenoviruses, BioLegend HLA-A antibody (Biolegend, W6/32) was used in immunohistochemistry on human samples at 1:50. Mucosal Immunol (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; fig 5
BioLegend HLA-A antibody (Biolegend, BB7.2) was used in flow cytometry on human samples (fig 5). PLoS Pathog (2015) ncbi
mouse monoclonal (BB7.2)
  • immunocytochemistry; human
BioLegend HLA-A antibody (BioLegend, 343304) was used in immunocytochemistry on human samples . Mol Med Rep (2015) ncbi
mouse monoclonal (W6/32)
  • other; human; fig 2
In order to characterize capabilities and potentials of extracellular vesicle (EV) array, BioLegend HLA-A antibody (BioLegend, 311402) was used in other on human samples (fig 2). J Extracell Vesicles (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; tbl 1
BioLegend HLA-A antibody (Biolegend, W.6.32) was used in flow cytometry on human samples (tbl 1). Cancer Immunol Immunother (2015) ncbi
mouse monoclonal (SF1-1.1)
  • flow cytometry; human; fig s1
BioLegend HLA-A antibody (Biolegend, 116616) was used in flow cytometry on human samples (fig s1). Proc Natl Acad Sci U S A (2015) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; fig 2
BioLegend HLA-A antibody (Biolegend, BB7.2) was used in flow cytometry on human samples (fig 2). Cancer Immunol Res (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1
  • immunocytochemistry; human; fig 3
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 1) and in immunocytochemistry on human samples (fig 3). Cancer Immunol Res (2015) ncbi
mouse monoclonal (W6/32)
  • ELISA; human; fig s1
BioLegend HLA-A antibody (Biolegend, 311402) was used in ELISA on human samples (fig s1). MAbs (2015) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; 15 ug/ml; fig 4
BioLegend HLA-A antibody (BioLegend, W6/32) was used in blocking or activating experiments on human samples at 15 ug/ml (fig 4). Vaccine (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1
BioLegend HLA-A antibody (Biolegend, W6/32) was used in flow cytometry on human samples (fig 1). J Infect Dis (2015) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human
BioLegend HLA-A antibody (BioLegend, BB7.2) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples . J Leukoc Biol (2014) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry; mouse; 1:50; fig 3
BioLegend HLA-A antibody (BioLegend, 311402) was used in immunohistochemistry on mouse samples at 1:50 (fig 3). Mol Cancer Res (2015) ncbi
mouse monoclonal (BB7.2)
BioLegend HLA-A antibody (BioLegend, BB7.2) was used . J Immunol (2014) ncbi
mouse monoclonal (W6/32)
  • western blot; human; fig 2
In order to study the effect of HCV infection on IFN-induced expression of MHC class I genes, BioLegend HLA-A antibody (BioLegend, W6/32) was used in western blot on human samples (fig 2). Gastroenterology (2014) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
BioLegend HLA-A antibody (Biolegend, 311403) was used in flow cytometry on human samples . PLoS ONE (2013) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 2d
In order to assess how different concentrations of IFN-gamma affect dendritic cells, BioLegend HLA-A antibody (BioLegend, W6/32) was used in flow cytometry on human samples (fig 2d). J Leukoc Biol (2014) ncbi
Invitrogen
mouse monoclonal (W6/32)
  • flow cytometry; mouse; loading ...
  • immunocytochemistry; human; fig s2d
Invitrogen HLA-A antibody (Thermo-Fisher, MA5-11723) was used in flow cytometry on mouse samples and in immunocytochemistry on human samples (fig s2d). J Exp Clin Cancer Res (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...
Invitrogen HLA-A antibody (eBioscienc, 12-9983-42) was used in flow cytometry on human samples . Nat Commun (2020) ncbi
rat monoclonal (YTH862.2)
  • flow cytometry; human; loading ...; fig 3e
Invitrogen HLA-A antibody (Invitrogen, MA1-80014) was used in flow cytometry on human samples (fig 3e). Breast Cancer Res (2019) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 1a
Invitrogen HLA-A antibody (eBioscience, W6/32) was used in flow cytometry on human samples (fig 1a). J Immunol (2018) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; loading ...; fig s2b
Invitrogen HLA-A antibody (eBiosciences, w6/32) was used in blocking or activating experiments on human samples (fig s2b). Nat Med (2018) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; fig 1d
  • flow cytometry; mouse; loading ...; fig 3d
Invitrogen HLA-A antibody (eBiosciences, 17-9876-42) was used in flow cytometry on human samples (fig 1d) and in flow cytometry on mouse samples (fig 3d). J Clin Invest (2017) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 1a
In order to evaluate the effectiveness of adoptive natural killer cell therapy against the pulmonary metastasis of Ewing sarcoma, Invitrogen HLA-A antibody (eBiosciences, W6/32) was used in flow cytometry on human samples (fig 1a). Oncoimmunology (2017) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 1a
In order to develop a recombinant Saccharomyces cerevisiae as a vehicle to deliver genes to primary human macrophages, Invitrogen HLA-A antibody (eBioscience, W6/32) was used in flow cytometry on human samples (fig 1a). Eur J Pharm Biopharm (2017) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry; human; 1:5000; loading ...
In order to assess the diagnostic value of myxovirus resistance A expression for dermatomyositis, Invitrogen HLA-A antibody (Thermo Fisher, W6/32) was used in immunohistochemistry on human samples at 1:5000. Neurology (2017) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 1d
In order to observe that the use of chimeric antigen receptor technology is a clinically applicable refinement of regulatory T cell therapy for organ transplantation, Invitrogen HLA-A antibody (eBioscience, BB7.2) was used in flow cytometry on human samples (fig 1d). Am J Transplant (2017) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s9a
Invitrogen HLA-A antibody (eBiosciences, W6/32) was used in flow cytometry on human samples (fig s9a). PLoS Pathog (2016) ncbi
mouse monoclonal (GAP.A3)
  • flow cytometry; human; loading ...; fig 2b
In order to investigate the role of Eomes in the retention of liver natural killer cells, Invitrogen HLA-A antibody (eBiosciences, GAP.A3) was used in flow cytometry on human samples (fig 2b). J Immunol (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1
In order to analyze how Saccharomyces cerevisiae interacts with different macrophage subsets, Invitrogen HLA-A antibody (eBioscience, W6/32) was used in flow cytometry on human samples (fig 1). Inflammation (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s9a
In order to discuss how signal peptidase complex proteins affect flaviviruses, Invitrogen HLA-A antibody (eBiosciences, W6/32) was used in flow cytometry on human samples (fig s9a). Nature (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:50; fig s2j
In order to develop and characterize a humanized ossicle xenotransplantation approach, Invitrogen HLA-A antibody (ebioscience, W6/32) was used in flow cytometry on human samples at 1:50 (fig s2j). Nat Med (2016) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry - paraffin section; human; 1:5000; fig 4
In order to determine if there is an association between inclusion body myositis and hepatitis C virus infection, Invitrogen HLA-A antibody (Thermo Fisher Scientific, W6/32) was used in immunohistochemistry - paraffin section on human samples at 1:5000 (fig 4). Neurology (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 6
In order to investigate the effect of SGI-110 on cancer testis antigen gene-regulated expression, Invitrogen HLA-A antibody (eBioscience, clone W6/32) was used in flow cytometry on human samples (fig 6). Leuk Res (2014) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
Invitrogen HLA-A antibody (eBioscience, W6/32) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (W6/32)
  • immunoprecipitation; human
  • western blot; human
In order to study lactacystin and IFN-gamma in human salivary glands, Invitrogen HLA-A antibody (Thermo Fisher, MA1-19027) was used in immunoprecipitation on human samples and in western blot on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (W6/32)
  • immunocytochemistry; human
Invitrogen HLA-A antibody (eBiosciences, 14-9983-82) was used in immunocytochemistry on human samples . J Biol Chem (2014) ncbi
mouse monoclonal (W6/32)
  • western blot; human
In order to report that the human herpesvirus-7 U21 gene product interferes with natural killer cell recognition, Invitrogen HLA-A antibody (Zymed Laboratories, W6/32) was used in western blot on human samples . PLoS Pathog (2011) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
Invitrogen HLA-A antibody (eBioscience, w6/32) was used in flow cytometry on human samples . Nat Immunol (2008) ncbi
Abcam
domestic rabbit polyclonal
Abcam HLA-A antibody (Abcam, ab168405) was used . Proc Natl Acad Sci U S A (2021) ncbi
domestic rabbit monoclonal (EPR1394Y)
  • western blot; human; 1:1000; loading ...; fig s2h
Abcam HLA-A antibody (Abcam, EPR1394Y) was used in western blot on human samples at 1:1000 (fig s2h). Nature (2020) ncbi
domestic rabbit monoclonal (EP1395Y)
  • western blot; human; 1:1000; loading ...; fig s2k
Abcam HLA-A antibody (Abcam, EP1395Y) was used in western blot on human samples at 1:1000 (fig s2k). Nature (2020) ncbi
domestic rabbit monoclonal (EP1395Y)
  • immunohistochemistry - frozen section; human; 1:100; loading ...; fig s1f
Abcam HLA-A antibody (ABCAM, ab52922) was used in immunohistochemistry - frozen section on human samples at 1:100 (fig s1f). Nature (2020) ncbi
rat monoclonal (ER-HR 52)
  • immunohistochemistry - frozen section; mouse; 1:100; loading ...; fig 4c
Abcam HLA-A antibody (Abcam, ER-HR 52) was used in immunohistochemistry - frozen section on mouse samples at 1:100 (fig 4c). Mol Neurodegener (2018) ncbi
domestic rabbit monoclonal (EP1395Y)
  • western blot; human; loading ...; fig 5a
Abcam HLA-A antibody (Abcam, ab52922) was used in western blot on human samples (fig 5a). Proteome Sci (2016) ncbi
domestic rabbit monoclonal (EP1395Y)
  • immunohistochemistry; rat; 1:100; fig 5b
In order to discuss factors to optimize the repair volumetric tissue defects, Abcam HLA-A antibody (Abcam, ab52922) was used in immunohistochemistry on rat samples at 1:100 (fig 5b). Sci Rep (2016) ncbi
domestic rabbit monoclonal (EP1395Y)
  • immunocytochemistry; human; 1:100; fig 6a
In order to develop a method to detect bone marrow-disseminated tumor cells in mice, Abcam HLA-A antibody (Abcam, EP1395Y) was used in immunocytochemistry on human samples at 1:100 (fig 6a). Oncotarget (2016) ncbi
rat monoclonal (ER-HR 52)
  • immunohistochemistry - frozen section; mouse; fig 5g
Abcam HLA-A antibody (Abcam, ab15681) was used in immunohistochemistry - frozen section on mouse samples (fig 5g). Sci Rep (2016) ncbi
domestic rabbit monoclonal (EP1395Y)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
Abcam HLA-A antibody (abcam, ab52922) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). PLoS ONE (2016) ncbi
domestic rabbit monoclonal (EPR1394Y)
  • immunohistochemistry - paraffin section; human; 1:500; tbl 5
Abcam HLA-A antibody (Epitomics, 2307-1) was used in immunohistochemistry - paraffin section on human samples at 1:500 (tbl 5). PLoS ONE (2016) ncbi
rat monoclonal (ER-HR 52)
  • immunocytochemistry; mouse; 1:200; loading ...; fig s8e
In order to find that coagulation factor XII modulates immune responses, Abcam HLA-A antibody (Abcam, ER-HR52) was used in immunocytochemistry on mouse samples at 1:200 (fig s8e). Nat Commun (2016) ncbi
domestic rabbit monoclonal (EP1395Y)
  • immunohistochemistry - paraffin section; human; 1:250; loading ...; fig 2c
Abcam HLA-A antibody (Abcam, ab52922) was used in immunohistochemistry - paraffin section on human samples at 1:250 (fig 2c). Int Wound J (2015) ncbi
Santa Cruz Biotechnology
mouse monoclonal (LY5.1)
  • western blot; human; loading ...; fig 3a
Santa Cruz Biotechnology HLA-A antibody (Santa Cruz Biotechnology, sc-52810) was used in western blot on human samples (fig 3a). Oncoimmunology (2018) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 3e, 3f
Santa Cruz Biotechnology HLA-A antibody (Santa Cruz, BB7.2) was used in flow cytometry on human samples (fig 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal
  • flow cytometry; human; loading ...; fig 3e, 3f
Santa Cruz Biotechnology HLA-A antibody (Santa Cruz, BB7.2) was used in flow cytometry on human samples (fig 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (C-6)
  • immunohistochemistry; human; 1:1300; fig s6
Santa Cruz Biotechnology HLA-A antibody (Santa Cruz Biotechnology, sc-365485) was used in immunohistochemistry on human samples at 1:1300 (fig s6). Nat Commun (2016) ncbi
mouse monoclonal (LY5.1)
  • western blot; human; 1:500; fig 2
Santa Cruz Biotechnology HLA-A antibody (Santa Cruz Technologies, SC-52810) was used in western blot on human samples at 1:500 (fig 2). Cancer Res (2015) ncbi
mouse monoclonal (W6/32)
  • western blot; human
Santa Cruz Biotechnology HLA-A antibody (Santa Cruz, sc-32235) was used in western blot on human samples . J Virol (2015) ncbi
Bio-Rad
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig s8c
Bio-Rad HLA-A antibody (AbD Serotec, BB7.2) was used in flow cytometry on human samples (fig s8c). Science (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 6a
Bio-Rad HLA-A antibody (AbD Serotec, BB7.2) was used in flow cytometry on human samples (fig 6a). PLoS ONE (2015) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human
Bio-Rad HLA-A antibody (Serotec, BB7.2) was used in flow cytometry on human samples . J Immunol (2014) ncbi
Miltenyi Biotec
human monoclonal (REA142)
  • flow cytometry; human; loading ...; fig 1d
In order to observe that the use of chimeric antigen receptor technology is a clinically applicable refinement of regulatory T cell therapy for organ transplantation, Miltenyi Biotec HLA-A antibody (Miltenyi-Biotec, REA142) was used in flow cytometry on human samples (fig 1d). Am J Transplant (2017) ncbi
Beckman Coulter
mouse monoclonal (B9.12.1)
  • flow cytometry; human; loading ...
Beckman Coulter HLA-A antibody (Immunotech, B9.12.1) was used in flow cytometry on human samples . Front Immunol (2019) ncbi
mouse monoclonal (B9.12.1)
  • flow cytometry; human; tbl 3
In order to document and describe lymphocyte predominant cells from lymph nodes involved in nodular lymphocyte predominant Hodgkin lymphoma, Beckman Coulter HLA-A antibody (Beckman Coulter (Immunotech), B9.12.1) was used in flow cytometry on human samples (tbl 3). Am J Pathol (2017) ncbi
mouse monoclonal (B9.12.1)
  • flow cytometry; human; fig 2
Beckman Coulter HLA-A antibody (Beckman, B9.12.1) was used in flow cytometry on human samples (fig 2). Sci Rep (2016) ncbi
mouse monoclonal (B9.12.1)
  • flow cytometry; human
Beckman Coulter HLA-A antibody (Beckman Coulter, B9.12.1) was used in flow cytometry on human samples . Transpl Immunol (2015) ncbi
BD Biosciences
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 1a
BD Biosciences HLA-A antibody (BD Biosciences, 561341) was used in flow cytometry on human samples (fig 1a). Proc Natl Acad Sci U S A (2021) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; 1:20; loading ...; fig 3s1b, c
BD Biosciences HLA-A antibody (BD Biosciences, 555552) was used in flow cytometry on human samples at 1:20 (fig 3s1b, c). elife (2021) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human
BD Biosciences HLA-A antibody (BD Biosciences, BB7.2) was used in flow cytometry on human samples . J Immunother Cancer (2020) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; loading ...; fig s4c
BD Biosciences HLA-A antibody (BD, 557348) was used in flow cytometry on human samples (fig s4c). Stem Cell Reports (2020) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; fig s4g
BD Biosciences HLA-A antibody (BD, 555554) was used in flow cytometry on human samples (fig s4g). Cell Death Differ (2019) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 2a
BD Biosciences HLA-A antibody (BD Biosciences, bb7.2) was used in flow cytometry on human samples (fig 2a). J Exp Med (2018) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; loading ...; fig 6c
BD Biosciences HLA-A antibody (BD Pharmingen, G46-2.6) was used in flow cytometry on human samples (fig 6c). Oncotarget (2017) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; loading ...; fig 2a
BD Biosciences HLA-A antibody (BD Biosciences, 555552) was used in flow cytometry on human samples (fig 2a). Oncotarget (2017) ncbi
mouse monoclonal (G46-2.6)
  • blocking or activating experiments; human; fig 6b
BD Biosciences HLA-A antibody (BD Biosciences, G46-2.6) was used in blocking or activating experiments on human samples (fig 6b). BMC Biotechnol (2017) ncbi
mouse monoclonal (BB7.2)
  • blocking or activating experiments; human; fig 6b
BD Biosciences HLA-A antibody (BD Biosciences, BB7.2) was used in blocking or activating experiments on human samples (fig 6b). BMC Biotechnol (2017) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 6b
BD Biosciences HLA-A antibody (BD Biosciences, 551230) was used in flow cytometry on human samples (fig 6b). J Immunol (2016) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; fig 1d
BD Biosciences HLA-A antibody (BD Biosciences, G46-2.6) was used in flow cytometry on human samples (fig 1d). J Virol (2016) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human
In order to investigate the impact of CD1c positive dendritic cells on immunogenic cell death, BD Biosciences HLA-A antibody (BD PharMingen, 555553) was used in flow cytometry on human samples . Oncoimmunology (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; loading ...; fig 5d
In order to generate a T-cell receptor-like monoclonal antibody (8F4) that binds the PR1/HLA-A2 complex and test it in preclinical models of acute myeloid leukemia, BD Biosciences HLA-A antibody (BD Pharmingen, BB7.2) was used in flow cytometry on human samples (fig 5d). Cytotherapy (2016) ncbi
mouse monoclonal (G46-2.6)
  • other; human; 500 ug/ml; fig 1
BD Biosciences HLA-A antibody (Becton Dickinson, 555551) was used in other on human samples at 500 ug/ml (fig 1). J Extracell Vesicles (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; fig 2
In order to develop an HLA-A2-specific chimeric antigen receptor and use it to generate alloantigen-specific human T regulatory cells, BD Biosciences HLA-A antibody (BD Biosciences, 551285) was used in flow cytometry on human samples (fig 2). J Clin Invest (2016) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; fig 1
BD Biosciences HLA-A antibody (BD Biosciences, 555552) was used in flow cytometry on human samples (fig 1). Int J Mol Med (2016) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, BD Biosciences HLA-A antibody (BD, 558570) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; fig 2
BD Biosciences HLA-A antibody (BD Biosciences, 561346) was used in flow cytometry on human samples (fig 2). Retrovirology (2015) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human; fig s1
In order to use 5-aza-2'-deoxycytidine to upregulate NY-ESO-1 expression by tumor cells, BD Biosciences HLA-A antibody (BD Biosciences, BB7.2) was used in flow cytometry on human samples (fig s1). PLoS ONE (2015) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human
BD Biosciences HLA-A antibody (BD Pharmingen, 555553) was used in flow cytometry on human samples . Cancer Lett (2015) ncbi
mouse monoclonal (G46-2.6)
  • immunohistochemistry; human; 1:200; fig 1
BD Biosciences HLA-A antibody (BD Pharmingen, 555552) was used in immunohistochemistry on human samples at 1:200 (fig 1). Cancer Res (2015) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human
In order to discuss the contribution of missense mutations in PDE3A to hypertension, BD Biosciences HLA-A antibody (BD Biosciences, 555552) was used in flow cytometry on human samples . Nat Genet (2015) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; tbl 1
BD Biosciences HLA-A antibody (BD Biosciences, G46-2.6) was used in flow cytometry on human samples (tbl 1). Cancer Immunol Immunother (2015) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human
BD Biosciences HLA-A antibody (BD Pharmingen, BB7.2) was used in flow cytometry on human samples . J Virol (2015) ncbi
mouse monoclonal (BB7.2)
  • flow cytometry; human
In order to test if Nef modifies the composition of exosomes released by T lymphocytes, BD Biosciences HLA-A antibody (BD Biosciences, BB7.2) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human
BD Biosciences HLA-A antibody (BD Biosciences, G46-2.6) was used in flow cytometry on human samples . Blood (2014) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human
In order to study the expression of the cancer stem cell markers CD24 abd CD44 in urothelial bladder cancer and their utility in prognosis and in predicting radical cystectomy outcome, BD Biosciences HLA-A antibody (BD Pharmingen, 555552) was used in flow cytometry on human samples . Urol Oncol (2014) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human
BD Biosciences HLA-A antibody (BD, 555553) was used in flow cytometry on human samples . Mol Cells (2013) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; 1:200
BD Biosciences HLA-A antibody (BD, 555551) was used in flow cytometry on human samples at 1:200. PLoS ONE (2013) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; tbl 2
BD Biosciences HLA-A antibody (BD Pharmingen, 555552) was used in flow cytometry on human samples (tbl 2). Cell Transplant (2014) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human
In order to discuss the use of PPR ligands as adjuvants and the use of interferon-gamma release assays as a diagnostic tool, BD Biosciences HLA-A antibody (BD, 561346) was used in flow cytometry on human samples . PLoS ONE (2012) ncbi
mouse monoclonal (G46-2.6)
  • flow cytometry; human; 1:5
BD Biosciences HLA-A antibody (BD Pharmingen, G46-2.6) was used in flow cytometry on human samples at 1:5. Microvasc Res (2012) ncbi
MilliporeSigma
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 1a
In order to elucidate the effects of pathogen recognition receptors on dendritic cell maturation, HIV infection, and on the quality of HIV-specific cytotoxic T-cell activation, MilliporeSigma HLA-A antibody (Sigma-Aldrich, W6/32) was used in flow cytometry on human samples (fig 1a). Eur J Immunol (2017) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human
  • immunoprecipitation; human
In order to study how Kaposi's sarcoma-associated herpes virus K3 viral gene product decreases cell surface MHC class I, MilliporeSigma HLA-A antibody (Sigma-Aldrich, w6/32) was used in flow cytometry on human samples and in immunoprecipitation on human samples . Biochem J (2015) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; fig 5
MilliporeSigma HLA-A antibody (Sigma, H1650) was used in flow cytometry on human samples (fig 5). J Virol (2014) ncbi
Articles Reviewed
  1. Malenica I, Adam J, Corgnac S, Mezquita L, Auclin E, Damei I, et al. Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. Nat Commun. 2021;12:5209 pubmed publisher
  2. Han E, Qian H, Jiang B, Figetakis M, Kosyakova N, Tellides G, et al. A therapeutic vascular conduit to support in vivo cell-secreted therapy. NPJ Regen Med. 2021;6:40 pubmed publisher
  3. Zhu Y, Xie J, Shi J. Rac1/ROCK-driven membrane dynamics promote natural killer cell cytotoxicity via granzyme-induced necroptosis. BMC Biol. 2021;19:140 pubmed publisher
  4. Wu S, Xiao Y, Wei J, Xu X, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9: pubmed publisher
  5. Nathan A, Rossin E, Kaseke C, Park R, Khatri A, Koundakjian D, et al. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell. 2021;: pubmed publisher
  6. McShan A, Devlin C, Morozov G, Overall S, Moschidi D, Akella N, et al. TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap. Nat Commun. 2021;12:3174 pubmed publisher
  7. Zhang Y, Chen Y, Li Y, Huang F, Luo B, Yuan Y, et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher
  8. Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582 pubmed publisher
  9. Sánchez del Campo L, Martí Díaz R, Montenegro M, González Guerrero R, Hernández Caselles T, Martínez Barba E, et al. MITF induces escape from innate immunity in melanoma. J Exp Clin Cancer Res. 2021;40:117 pubmed publisher
  10. Hsiue E, Wright K, Douglass J, Hwang M, Mog B, Pearlman A, et al. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021;371: pubmed publisher
  11. Devilbiss A, Zhao Z, Martin Sandoval M, Ubellacker J, Tasdogan A, Agathocleous M, et al. Metabolomic profiling of rare cell populations isolated by flow cytometry from tissues. elife. 2021;10: pubmed publisher
  12. Li Z, Zhang H, Huang Y, Huang J, Sun P, Zhou N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806 pubmed publisher
  13. Zurli V, Montecchi T, Heilig R, Poschke I, Volkmar M, Wimmer G, et al. Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. Sci Signal. 2020;13: pubmed publisher
  14. Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100-105 pubmed publisher
  15. Marotte L, Simon S, Vignard V, Dupré E, Gantier M, Cruard J, et al. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes. J Immunother Cancer. 2020;8: pubmed publisher
  16. Yu K, Lin C, Hatcher A, Lozzi B, Kong K, Huang Hobbs E, et al. PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. Nature. 2020;578:166-171 pubmed publisher
  17. Mosaheb M, Dobrikova E, Brown M, Yang Y, Cable J, Okada H, et al. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun. 2020;11:524 pubmed publisher
  18. Queckborner S, Syk Lundberg E, Gemzell Danielsson K, Davies L. Endometrial stromal cells exhibit a distinct phenotypic and immunomodulatory profile. Stem Cell Res Ther. 2020;11:15 pubmed publisher
  19. Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, et al. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020;14:49-59 pubmed publisher
  20. Wang B, Saito Y, Nishimura M, Ren Z, Tjan L, Refaat A, et al. An Animal Model That Mimics Human Herpesvirus 6B Pathogenesis. J Virol. 2020;94: pubmed publisher
  21. Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217-223 pubmed publisher
  22. Sanz Ortega L, Rojas J, Portilla Y, Pérez Yagüe S, Barber D. Magnetic Nanoparticles Attached to the NK Cell Surface for Tumor Targeting in Adoptive Transfer Therapies Does Not Affect Cellular Effector Functions. Front Immunol. 2019;10:2073 pubmed publisher
  23. Merola J, Reschke M, Pierce R, Qin L, Spindler S, Baltazar T, et al. Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression. JCI Insight. 2019;4: pubmed publisher
  24. Findlay E, Currie A, Zhang A, Ovciarikova J, Young L, Stevens H, et al. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology. 2019;8:1608106 pubmed publisher
  25. Rosshart S, Herz J, Vassallo B, Hunter A, Wall M, Badger J, et al. Laboratory mice born to wild mice have natural microbiota and model human immune responses. Science. 2019;365: pubmed publisher
  26. Verma V, Shrimali R, Ahmad S, Dai W, Wang H, Lu S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019;20:1231-1243 pubmed publisher
  27. Dangaj D, Bruand M, Grimm A, Ronet C, Barras D, Duttagupta P, et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell. 2019;35:885-900.e10 pubmed publisher
  28. Sabol R, Bowles A, Côté A, Wise R, O Donnell B, Matossian M, et al. Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models. Breast Cancer Res. 2019;21:67 pubmed publisher
  29. Pavel Dinu M, Wiebking V, Dejene B, Srifa W, Mantri S, Nicolas C, et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat Commun. 2019;10:1634 pubmed publisher
  30. Fauster A, Rebsamen M, Willmann K, César Razquin A, Girardi E, Bigenzahn J, et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 2019;26:1138-1155 pubmed publisher
  31. Walwyn Brown K, Guldevall K, Saeed M, Pende D, Önfelt B, MacDonald A, et al. Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1. J Immunol. 2018;201:2028-2041 pubmed publisher
  32. Marijt K, Blijleven L, Verdegaal E, Kester M, Kowalewski D, Rammensee H, et al. Identification of non-mutated neoantigens presented by TAP-deficient tumors. J Exp Med. 2018;215:2325-2337 pubmed publisher
  33. Nardo G, Trolese M, Verderio M, Mariani A, De Paola M, Riva N, et al. Counteracting roles of MHCI and CD8+ T cells in the peripheral and central nervous system of ALS SOD1G93A mice. Mol Neurodegener. 2018;13:42 pubmed publisher
  34. Wilson K, Liu H, Healey G, Vuong V, Ishido S, Herold M, et al. MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway. PLoS ONE. 2018;13:e0200540 pubmed publisher
  35. Heusinger E, Deppe K, Sette P, Krapp C, Kmiec D, Kluge S, et al. Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2. J Virol. 2018;92: pubmed publisher
  36. Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed publisher
  37. Zacharakis N, Chinnasamy H, Black M, Xu H, Lu Y, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24:724-730 pubmed publisher
  38. Liao Y, Ivanova L, Sivalenka R, Plumer T, Zhu H, Zhang X, et al. Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model. Stem Cells Transl Med. 2018;7:530-542 pubmed publisher
  39. Liu R, Merola J, Manes T, Qin L, Tietjen G, Lopez Giraldez F, et al. Interferon-γ converts human microvascular pericytes into negative regulators of alloimmunity through induction of indoleamine 2,3-dioxygenase 1. JCI Insight. 2018;3: pubmed publisher
  40. Jung Y, Cackowski F, Yumoto K, Decker A, Wang J, Kim J, et al. CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res. 2018;78:2026-2039 pubmed publisher
  41. Ende Z, Deymier M, Claiborne D, Prince J, Mónaco D, Kilembe W, et al. HLA Class I Downregulation by HIV-1 Variants from Subtype C Transmission Pairs. J Virol. 2018;92: pubmed publisher
  42. Barkal A, Weiskopf K, Kao K, Gordon S, Rosental B, Yiu Y, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19:76-84 pubmed publisher
  43. Mwimanzi F, Toyoda M, Mahiti M, Mann J, Martin J, Bangsberg D, et al. Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. J Virol. 2018;92: pubmed publisher
  44. Shen T, Chen Z, Zhao Z, Wu J. Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer. Oncotarget. 2017;8:60975-60986 pubmed publisher
  45. Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher
  46. Zhang X, Lian X, Dai Z, Zheng H, Chen X, Zheng Y. ?3-Deletion Isoform of HLA-A11 Modulates Cytotoxicity of NK Cells: Correlations with HIV-1 Infection of Cells. J Immunol. 2017;199:2030-2042 pubmed publisher
  47. Gotsbacher M, Cho S, Kwon H, Karuso P. Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans. Proteome Sci. 2016;15:16 pubmed publisher
  48. Chang A, Dao T, Gejman R, Jarvis C, Scott A, Dubrovsky L, et al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest. 2017;127:2705-2718 pubmed publisher
  49. Johnson D, Wayt J, Wilson J, Donaldson J. Arf6 and Rab22 mediate T cell conjugate formation by regulating clathrin-independent endosomal membrane trafficking. J Cell Sci. 2017;130:2405-2415 pubmed publisher
  50. Tong A, Hashem H, Eid S, Allen F, Kingsley D, Huang A. Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. Oncoimmunology. 2017;6:e1303586 pubmed publisher
  51. Seif M, Hoppstädter J, Breinig F, Kiemer A. Yeast-mediated mRNA delivery polarizes immuno-suppressive macrophages towards an immuno-stimulatory phenotype. Eur J Pharm Biopharm. 2017;117:1-13 pubmed publisher
  52. Cardinaud S, Urrutia A, Rouers A, Coulon P, Kervevan J, Richetta C, et al. Triggering of TLR-3, -4, NOD2, and DC-SIGN reduces viral replication and increases T-cell activation capacity of HIV-infected human dendritic cells. Eur J Immunol. 2017;47:818-829 pubmed publisher
  53. Ren J, Zhang X, Liu X, Fang C, Jiang S, June C, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017;8:17002-17011 pubmed publisher
  54. Zhu J, Cifuentes H, Reynolds J, Lamba D. Immunosuppression via Loss of IL2rγ Enhances Long-Term Functional Integration of hESC-Derived Photoreceptors in the Mouse Retina. Cell Stem Cell. 2017;20:374-384.e5 pubmed publisher
  55. Ouisse L, Gautreau Rolland L, Devilder M, Osborn M, Moyon M, Visentin J, et al. Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies. BMC Biotechnol. 2017;17:3 pubmed publisher
  56. Uruha A, Nishikawa A, Tsuburaya R, Hamanaka K, Kuwana M, Watanabe Y, et al. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology. 2017;88:493-500 pubmed publisher
  57. Boardman D, Philippeos C, Fruhwirth G, Ibrahim M, Hannen R, Cooper D, et al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant. 2017;17:931-943 pubmed publisher
  58. Fromm J, Thomas A, Wood B. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol. 2017;187:304-317 pubmed publisher
  59. Kim J, Ko I, Atala A, Yoo J. Progressive Muscle Cell Delivery as a Solution for Volumetric Muscle Defect Repair. Sci Rep. 2016;6:38754 pubmed publisher
  60. Tomic A, Varanasi P, Golemac M, Malic S, Riese P, Borst E, et al. Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand. PLoS Pathog. 2016;12:e1006015 pubmed publisher
  61. Dellgren C, Ekwelum V, Ormhøj M, Pallesen N, Knudsen J, Nehlin J, et al. Low Constitutive Cell Surface Expression of HLA-B Is Caused by a Posttranslational Mechanism Involving Glu180 and Arg239. J Immunol. 2016;197:4807-4816 pubmed
  62. Dever D, Bak R, Reinisch A, Camarena J, Washington G, Nicolas C, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539:384-389 pubmed publisher
  63. Cuff A, Robertson F, Stegmann K, Pallett L, Maini M, Davidson B, et al. Eomeshi NK Cells in Human Liver Are Long-Lived and Do Not Recirculate but Can Be Replenished from the Circulation. J Immunol. 2016;197:4283-4291 pubmed
  64. Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, et al. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113:E6467-E6475 pubmed
  65. Trautz B, Pierini V, Wombacher R, Stolp B, Chase A, Pizzato M, et al. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor. J Virol. 2016;90:10915-10927 pubmed publisher
  66. Valkenburg K, Amend S, Verdone J, van der Toom E, Hernandez J, Gorin M, et al. A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow. Oncotarget. 2016;7:69794-69803 pubmed publisher
  67. Huang M, Zhang W, Guo J, Wei X, Phiwpan K, Zhang J, et al. Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation. Sci Rep. 2016;6:33612 pubmed publisher
  68. Di Blasio S, Wortel I, van Bladel D, de Vries L, Duiveman de Boer T, Worah K, et al. Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology. 2016;5:e1192739 pubmed publisher
  69. Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, et al. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213:2065-80 pubmed publisher
  70. Saranchova I, Han J, Huang H, Fenninger F, Choi K, Munro L, et al. Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep. 2016;6:30555 pubmed publisher
  71. Landtwing V, Raykova A, Pezzino G, Beziat V, Marcenaro E, Graf C, et al. Cognate HLA absence in trans diminishes human NK cell education. J Clin Invest. 2016;126:3772-3782 pubmed publisher
  72. Yamamoto M, Zhao M, Hiroshima Y, Zhang Y, Shurell E, Eilber F, et al. Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. PLoS ONE. 2016;11:e0160882 pubmed publisher
  73. Sadallah S, Schmied L, Eken C, Charoudeh H, Amicarella F, Schifferli J. Platelet-Derived Ectosomes Reduce NK Cell Function. J Immunol. 2016;197:1663-71 pubmed publisher
  74. Maglietta A, Maglietta R, Staiano T, Bertoni R, Ancona N, Marra G, et al. The Immune Landscapes of Polypoid and Nonpolypoid Precancerous Colorectal Lesions. PLoS ONE. 2016;11:e0159373 pubmed publisher
  75. Seif M, Philippi A, Breinig F, Kiemer A, Hoppstädter J. Yeast (Saccharomyces cerevisiae) Polarizes Both M-CSF- and GM-CSF-Differentiated Macrophages Toward an M1-Like Phenotype. Inflammation. 2016;39:1690-703 pubmed publisher
  76. Terracina K, Graham L, Payne K, Manjili M, Baek A, Damle S, et al. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunol Immunother. 2016;65:1061-73 pubmed publisher
  77. Zhang R, Miner J, Gorman M, Rausch K, Ramage H, White J, et al. A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature. 2016;535:164-8 pubmed
  78. Liu C, LeClair P, Monajemi M, Sly L, Reid G, Lim C. α-Integrin expression and function modulates presentation of cell surface calreticulin. Cell Death Dis. 2016;7:e2268 pubmed publisher
  79. Ma Q, Garber H, Lu S, He H, Tallis E, Ding X, et al. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016;18:985-94 pubmed publisher
  80. Reinisch A, Thomas D, Corces M, Zhang X, Gratzinger D, Hong W, et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat Med. 2016;22:812-21 pubmed publisher
  81. Strønen E, Toebes M, Kelderman S, van Buuren M, Yang W, van Rooij N, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016;352:1337-41 pubmed publisher
  82. Reches A, Nachmani D, Berhani O, Duev Cohen A, Shreibman D, Ophir Y, et al. HNRNPR Regulates the Expression of Classical and Nonclassical MHC Class I Proteins. J Immunol. 2016;196:4967-76 pubmed publisher
  83. Göbel K, Pankratz S, Asaridou C, Herrmann A, Bittner S, Merker M, et al. Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun. 2016;7:11626 pubmed publisher
  84. Belov L, Matic K, Hallal S, Best O, Mulligan S, Christopherson R. Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. J Extracell Vesicles. 2016;5:25355 pubmed publisher
  85. Li H, Borrego F, Nagata S, Tolnay M. Fc Receptor-like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory B Cells. J Immunol. 2016;196:4064-74 pubmed publisher
  86. Macdonald K, Hoeppli R, Huang Q, Gillies J, Luciani D, Orban P, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413-24 pubmed publisher
  87. Chung S, Rho S, Kim G, Kim S, Baek K, Kang M, et al. Human umbilical cord blood mononuclear cells and chorionic plate-derived mesenchymal stem cells promote axon survival in a rat model of optic nerve crush injury. Int J Mol Med. 2016;37:1170-80 pubmed publisher
  88. Apostolidis S, Rodríguez Rodríguez N, Suárez Fueyo A, Dioufa N, Ozcan E, Crispín J, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17:556-64 pubmed publisher
  89. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  90. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher
  91. Ludigs K, Jandus C, Utzschneider D, Staehli F, Bessoles S, Dang A, et al. NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nat Commun. 2016;7:10554 pubmed publisher
  92. Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed publisher
  93. Uruha A, Noguchi S, Hayashi Y, Tsuburaya R, Yonekawa T, Nonaka I, et al. Hepatitis C virus infection in inclusion body myositis: A case-control study. Neurology. 2016;86:211-7 pubmed publisher
  94. Heigele A, Joas S, Regensburger K, Kirchhoff F. Increased susceptibility of CD4+ T cells from elderly individuals to HIV-1 infection and apoptosis is associated with reduced CD4 and enhanced CXCR4 and FAS surface expression levels. Retrovirology. 2015;12:86 pubmed publisher
  95. Klar A, Gopinadh J, Kleber S, Wadle A, Renner C. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing. PLoS ONE. 2015;10:e0139221 pubmed publisher
  96. Thuring C, Follin E, Geironson L, Freyhult E, Junghans V, Harndahl M, et al. HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma. Br J Cancer. 2015;113:952-62 pubmed publisher
  97. Fernandez L, Valentin J, Zalacain M, Leung W, Patino Garcia A, Perez Martinez A. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. Cancer Lett. 2015;368:54-63 pubmed publisher
  98. Parkinson M, Piper S, Bright N, Evans J, Boname J, Bowers K, et al. A non-canonical ESCRT pathway, including histidine domain phosphotyrosine phosphatase (HD-PTP), is used for down-regulation of virally ubiquitinated MHC class I. Biochem J. 2015;471:79-88 pubmed publisher
  99. Li Z, Xu X, Weiss I, Jacobson O, Murphy P. Pre-treatment of allogeneic bone marrow recipients with the CXCR4 antagonist AMD3100 transiently enhances hematopoietic chimerism without promoting donor-specific skin allograft tolerance. Transpl Immunol. 2015;33:125-9 pubmed publisher
  100. Huygens C, Liénart S, Dedobbeleer O, Stockis J, Gauthy E, Coulie P, et al. Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells. J Biol Chem. 2015;290:20105-16 pubmed publisher
  101. Herz J, Johnson K, McGavern D. Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells. J Exp Med. 2015;212:1153-69 pubmed publisher
  102. Yawata N, Selva K, Liu Y, Tan K, Lee A, Siak J, et al. Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection. Mucosal Immunol. 2016;9:159-70 pubmed publisher
  103. Miranda A, Funes J, Sánchez N, Limia C, Mesa M, Quezada S, et al. Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure. Cancer Res. 2015;75:3032-42 pubmed publisher
  104. Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed publisher
  105. Guo X, Liu T, Shi H, Wang J, Ji P, Wang H, et al. Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells. J Virol. 2015;89:7636-45 pubmed publisher
  106. Maass P, Aydin A, Luft F, Schächterle C, Weise A, Stricker S, et al. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat Genet. 2015;47:647-53 pubmed publisher
  107. Tang B, Zhou W, Du J, He Y, Li Y. Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8. Mol Med Rep. 2015;12:1741-52 pubmed publisher
  108. Walseng E, Wälchli S, Fallang L, Yang W, Vefferstad A, Areffard A, et al. Soluble T-cell receptors produced in human cells for targeted delivery. PLoS ONE. 2015;10:e0119559 pubmed publisher
  109. Jørgensen M, Bæk R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles. 2015;4:26048 pubmed publisher
  110. Boerman G, van Ostaijen Ten Dam M, Kraal K, Santos S, Ball L, Lankester A, et al. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells. Cancer Immunol Immunother. 2015;64:573-83 pubmed publisher
  111. Cheah M, Chen J, Sahoo D, Contreras Trujillo H, Volkmer A, Scheeren F, et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A. 2015;112:4725-30 pubmed publisher
  112. Bradley S, Chen Z, Melendez B, Talukder A, Khalili J, Rodríguez Cruz T, et al. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res. 2015;3:602-9 pubmed publisher
  113. Nambiar J, Clarke A, Shim D, Mabon D, Tian C, Windloch K, et al. Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model. MAbs. 2015;7:638-50 pubmed publisher
  114. Tomimaru Y, Mishra S, Safran H, Charpentier K, Martin W, De Groot A, et al. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine. 2015;33:1256-66 pubmed publisher
  115. Khan A, Srivastava R, Spencer D, Garg S, Fremgen D, Vahed H, et al. Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpes. J Virol. 2015;89:3776-92 pubmed publisher
  116. Esquivel E, Maeda A, Eguchi H, Asada M, Sugiyama M, Manabe C, et al. Suppression of human macrophage-mediated cytotoxicity by transgenic swine endothelial cell expression of HLA-G. Transpl Immunol. 2015;32:109-15 pubmed publisher
  117. de Carvalho J, de Castro R, da Silva E, Silveira P, da Silva Januário M, Arruda E, et al. Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection. PLoS ONE. 2014;9:e113691 pubmed publisher
  118. Boltjes A, van Montfoort N, Biesta P, Op den Brouw M, Kwekkeboom J, van der Laan L, et al. Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function. J Infect Dis. 2015;211:1268-78 pubmed publisher
  119. Matheson N, Peden A, Lehner P. Antibody-free magnetic cell sorting of genetically modified primary human CD4+ T cells by one-step streptavidin affinity purification. PLoS ONE. 2014;9:e111437 pubmed publisher
  120. Gabaev I, Elbasani E, Ameres S, Steinbrück L, Stanton R, Döring M, et al. Expression of the human cytomegalovirus UL11 glycoprotein in viral infection and evaluation of its effect on virus-specific CD8 T cells. J Virol. 2014;88:14326-39 pubmed publisher
  121. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Karbach J, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res. 2014;38:1332-41 pubmed publisher
  122. Abramowski P, Ogrodowczyk C, Martin R, Pongs O. A truncation variant of the cation channel P2RX5 is upregulated during T cell activation. PLoS ONE. 2014;9:e104692 pubmed publisher
  123. Chao Y, Kaliaperumal N, Chretien A, Tang S, Lee B, Poidinger M, et al. Human plasmacytoid dendritic cells regulate IFN-α production through activation-induced splicing of IL-18Rα. J Leukoc Biol. 2014;96:1037-46 pubmed publisher
  124. Davey M, Morgan M, Liuzzi A, Tyler C, Khan M, Szakmany T, et al. Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells. J Immunol. 2014;193:3704-3716 pubmed publisher
  125. Jung Y, Wang J, Lee E, McGee S, Berry J, Yumoto K, et al. Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res. 2015;13:197-207 pubmed publisher
  126. Arellano Garcia M, Misuno K, Tran S, Hu S. Interferon-? induces immunoproteasomes and the presentation of MHC I-associated peptides on human salivary gland cells. PLoS ONE. 2014;9:e102878 pubmed publisher
  127. Lee Chang C, Bodogai M, Moritoh K, Olkhanud P, Chan A, Croft M, et al. Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity. Blood. 2014;124:1450-9 pubmed publisher
  128. Ameres S, Besold K, Plachter B, Moosmann A. CD8 T cell-evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity. J Immunol. 2014;192:5894-905 pubmed publisher
  129. Hofner T, Macher Goeppinger S, Klein C, Schillert A, Eisen C, Wagner S, et al. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urol Oncol. 2014;32:678-86 pubmed publisher
  130. Kang W, Sung P, Park S, Yoon S, Chang D, Kim S, et al. Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions. Gastroenterology. 2014;146:1351-60.e1-4 pubmed publisher
  131. Stahlschmidt W, Robertson M, Robinson P, McCluskey A, Haucke V. Clathrin terminal domain-ligand interactions regulate sorting of mannose 6-phosphate receptors mediated by AP-1 and GGA adaptors. J Biol Chem. 2014;289:4906-18 pubmed publisher
  132. Shanmugam V, Tassi E, Schmidt M, McNish S, Baker S, Attinger C, et al. Utility of a human-mouse xenograft model and in vivo near-infrared fluorescent imaging for studying wound healing. Int Wound J. 2015;12:699-705 pubmed publisher
  133. Han J, Rho S, Lee J, Bae J, Park S, Lee S, et al. Human cytomegalovirus (HCMV) US2 protein interacts with human CD1d (hCD1d) and down-regulates invariant NKT (iNKT) cell activity. Mol Cells. 2013;36:455-64 pubmed publisher
  134. Fuentes T, Appleby N, Tsay E, Martinez J, Bailey L, Hasaniya N, et al. Human neonatal cardiovascular progenitors: unlocking the secret to regenerative ability. PLoS ONE. 2013;8:e77464 pubmed publisher
  135. Svajger U, Obermajer N, Jeras M. IFN-?-rich environment programs dendritic cells toward silencing of cytotoxic immune responses. J Leukoc Biol. 2014;95:33-46 pubmed publisher
  136. Zuliani T, Saiagh S, Knol A, Esbelin J, Dreno B. Fetal fibroblasts and keratinocytes with immunosuppressive properties for allogeneic cell-based wound therapy. PLoS ONE. 2013;8:e70408 pubmed publisher
  137. Jacobs S, Plessers J, Pinxteren J, Roobrouck V, Verfaillie C, Van Gool S. Mutual interaction between human multipotent adult progenitor cells and NK cells. Cell Transplant. 2014;23:1099-110 pubmed publisher
  138. Gaur R, Suhosk M, Banaei N. In vitro immunomodulation of a whole blood IFN-? release assay enhances T cell responses in subjects with latent tuberculosis infection. PLoS ONE. 2012;7:e48027 pubmed publisher
  139. Sölder E, Böckle B, Nguyen V, Fürhapter C, Obexer P, Erdel M, et al. Isolation and characterization of CD133+CD34+VEGFR-2+CD45- fetal endothelial cells from human term placenta. Microvasc Res. 2012;84:65-73 pubmed publisher
  140. Schneider C, Hudson A. The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB. PLoS Pathog. 2011;7:e1002362 pubmed publisher
  141. Di Pucchio T, Chatterjee B, Smed Sorensen A, Clayton S, Palazzo A, Montes M, et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol. 2008;9:551-7 pubmed publisher